Marker Therapeutics (MRKR) EV/EBITDA: History & Chart

Marker Therapeutics, Inc.(MRKR)

Biotechnology · Houston, TX

$1.02-0.04 (-3.77%)

Delayed quote: Oct 6, 2026, 3:39 PM EDT

About Marker Therapeutics, Inc.

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on discovering and bringing to market a variety of T cell-based immunotherapies and peptide-based vaccines. These cutting-edge treatments are engineered to address both blood cancers (hematological malignancies) and solid tumor conditions across the United States. A cornerstone of their approach is the proprietary MultiTAA-specific T cell technology. This method involves producing T cells that are not genetically modified but are specifically designed to target tumors. These specialized T cells can identify multiple antigens associated with tumors, allowing them to effectively eliminate cancer cells that express these markers. Marker Therapeutics' MultiTAA-specific T cell therapies encompass patient-derived (autologous) T cells for treating lymphoma and various solid tumors, as well as donor-derived (allogeneic) T cells for acute myeloid leukemia and acute lymphoblastic leukemia. They also provide "off-the-shelf" solutions applicable to a range of diseases. In addition to T cell therapies, the company is advancing peptide-based immunotherapeutic vaccines. This pipeline includes TPIV100/110, developed to combat breast and ovarian cancer cells, and TPIV200, which is currently undergoing Phase 2 clinical trials for the treatment of breast and ovarian cancers. Founded in 1999, Marker Therapeutics maintains its headquarters in Houston, Texas.

Houston, TX

5 employees

www.markertherapeutics.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Juan F. Vera

View full financials

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Marker Therapeutics, Inc. (MRKR)	$17.01M	N/A	N/A	N/A	N/A
Lipocine Inc. (LPCN)vs ›	$17.11M	N/A	19.19x	19.19x	19.19x
PAVmed Inc. (PAVM)vs ›	$17.27M	N/A	N/A	N/A	N/A
Palatin Technologies, Inc. (PTN)vs ›	$16.74M	N/A	197.20x	1380.98x	1380.98x
TScan Therapeutics, Inc. (TCRX)vs ›	$16.67M	N/A	N/A	N/A	N/A
Bionano Genomics, Inc. (BNGO)vs ›	$16.58M	N/A	N/A	N/A	N/A
Cosmos Health Inc. (COSM)vs ›	$17.57M	N/A	47.55x	64.91x	64.91x
Dyadic International, Inc. (DYAI)vs ›	$16.43M	N/A	95.14x	74.72x	74.72x
Estrella Immunopharma, Inc. (ESLA)vs ›	$18.18M	N/A	N/A	N/A	N/A
P3 Health Partners Inc. (PIII)vs ›	$18.18M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

EV/EBITDA RATIO

TTM

Marker Therapeutics, Inc. (MRKR)

$17.01M

N/A

Lipocine Inc. (LPCN)vs ›

$17.11M

N/A

19.19x

PAVmed Inc. (PAVM)vs ›